The effects of direct hemoperfusion with polymyxin B-immobilized fiber in patients with acute exacerbation of interstitial lung disease
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Acute exacerbation of interstitial lung disease (AE-ILD) causes clinically significant deterioration and has an extremely poor prognosis with high mortality. Recently, several studies reported the effectiveness of direct hemoperfusion with a polymyxin B-immobilized fiber column (PMX-DHP) in patients with AE-ILD as a potential therapy. This study describes the clinical effectiveness and safety of PMX-DHP in patients with AE-ILD. Methods: We retrospectively reviewed the medical records of 10 patients (11 episodes) with AE-ILD treated with PMX-DHP from January 2018 to June 2019. We compared laboratory and physiologic data of the ratio of partial pressure arterial oxygen to fraction of inspired oxygen (P/F ratio) and level of inflammatory markers before and after implementation of PMX-DHP. Results: Ten patients were included according to the 2016 revised definition of acute exacerbation of idiopathic pulmonary fibrosis (IPF). Nine patients had IPF and one patient had fibrotic nonspecific interstitial pneumonia. Most patients (90.9%) were treated with a steroid pulse, and four patients (36.4%) were treated with an immunosuppressant. The median number of PMX-DHP cycles was 2, and the median duration of each cycle was 6 hours. After PMX-DHP, the mean P/F ratio improved (86 [range, 63–106] vs. 145 [86–260], P=0.030) and interleukin-6 and c-reactive protein decreased (79 [35–640] vs. 10 [5–25], P=0.018 and 14 [4–21] vs. 5 [2–6], P=0.019, respectively). The 30-day mortality rate was 27.3% and the 90-day mortality rate was 72.7%. Conclusions: PMX-DHP treatment improved P/F ratio and reduced inflammatory markers in AE-ILD patients.
Abstract
Background: Acute exacerbation of interstitial lung disease (AE-ILD) causes clinically significant deterioration and has an extremely poor prognosis with high mortality. Recently, several studies reported the effectiveness of direct hemoperfusion with a polymyxin B-immobilized fiber column (PMX-DHP) in patients with AE-ILD as a potential therapy. This study describes the clinical effectiveness and safety of PMX-DHP in patients with AE-ILD. Methods: We retrospectively reviewed the medical records of 10 patients (11 episodes) with AE-ILD treated with PMX-DHP from January 2018 to June 2019. We compared laboratory and physiologic data of the ratio of partial pressure arterial oxygen to fraction of inspired oxygen (P/F ratio) and level of inflammatory markers before and after implementation of PMX-DHP. Results: Ten patients were included according to the 2016 revised definition of acute exacerbation of idiopathic pulmonary fibrosis (IPF). Nine patients had IPF and one patient had fibrotic nonspecific interstitial pneumonia. Most patients (90.9%) were treated with a steroid pulse, and four patients (36.4%) were treated with an immunosuppressant. The median number of PMX-DHP cycles was 2, and the median duration of each cycle was 6 hours. After PMX-DHP, the mean P/F ratio improved (86 [range, 63–106] vs. 145 [86–260], P=0.030) and interleukin-6 and c-reactive protein decreased (79 [35–640] vs. 10 [5–25], P=0.018 and 14 [4–21] vs. 5 [2–6], P=0.019, respectively). The 30-day mortality rate was 27.3% and the 90-day mortality rate was 72.7%. Conclusions: PMX-DHP treatment improved P/F ratio and reduced inflammatory markers in AE-ILD patients.
참고문헌 (29)
- Leuschner G, "Acute exacerbation in interstitial lung disease", Front Med(Lausanne), 4, pp.176~ (2017)
- Usui Y, "A cohort study of mortality predictors in patients with acute exacerbation of chronic fibrosing interstitial pneumonia", BMJ Open, 3, pp.e002971~ (2013)
- Song JW, "Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome", Eur Respir J, 37, pp.356~363 (2011)
- Kim DS, "Acute exacerbation of idiopathic pulmonary fibrosis : frequency and clinical features", Eur Respir J, 27, pp.143~150 (2006)
- Al-Hameed FM, "Outcome of patients admitted to the intensive care unit for acute exacerbation of idiopathic pulmonary fibrosis", Can Respir J, 11, pp.117~122 (2004)
- Shoji H, "Extracorporeal endotoxin removal for the treatment of sepsis : endotoxin adsorption cartridge(Toraymyxin)", Ther Apher Dial, 7, pp.108~114 (2003)
- Nakamura T, "Effect of polymyxin B-immobilized fiber on blood metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 levels in acute respiratory distress syndrome patients", Blood Purif, 22, pp.256~260 (2004)
- Tsushima K, "Direct hemoperfusion using a polymyxin B immobilized column improves acute respiratory distress syndrome", J Clin Apher, 17, pp.97~102 (2002)
- Utsunomiya T, "Cytokine adsorption to polymyxin B-immobilized fiber : an in vitro Study", Blood Purif, 50, pp.230~237 (2021)
- Abe S, "Polymyxin B-immobilized fiber column(PMX)treatment for idiopathic pulmonary fibrosis with acute exacerbation : a multicenter retrospective analysis", Intern Med, 51, pp.1487~1491 (2012)
- Hara S, "Direct hemoperfusion using immobilized polymyxin B in patients with rapidly progressive interstitial pneumonias : a retrospective study", Respiration, 81, pp.107~117 (2011)
- Seo Y, "Beneficial effect of polymyxin B-immobilized fiber column(PMX)hemoperfusion treatment on acute exacerbation of idiopathic pulmonary fibrosis", Intern Med, 45, pp.1033~1038 (2006)
- Travis WD, "An official American Thoracic Society", European Respiratory Society statement : update of the international multidisciplinary classification of the idiopathic interstitial pneumonias, 2013, pp.188, 733~748
- Raghu G, "An official ATS", ERS, ALAT statement : idiopathic pulmonary fibrosis : evidence-based guidelines for diagnosis and management, pp.Am J Respir Crit Care Med, 2011[DOI]
- Collard HR, "Acute exacerbation of idiopathic pulmonary fibrosis. an international working group report", Am J Respir Crit Care Med, 194, pp.265~275 (2016)
- Wanger J, "Standardisation of the measurement of lung volumes", Eur Respir J, 26, pp.511~522 (2005)
- Miller MR, "Standardisation of spirometry", Eur Respir J, 26, pp.319~338 (2005)
- Holland AE, "An official European Respiratory Society", American Thoracic Society technical standard : field walking tests in chronic respiratory disease, 2014, pp.44, 1428~1446
- Ley B, "A multidimensional index and staging system for idiopathic pulmonary fibrosis", Ann Intern Med, 156, pp.684~691 (2012)
- Ueno T, "HMGB-1 as a useful prognostic biomarker in sepsis-induced organ failure in patients undergoing PMX-DHP", J Surg Res, 171, pp.183~190 (2011)
- Tani T, "Correlation between plasma endotoxin, plasma cytokines, and plasminogen activator inhibitor-1 activities in septic patients", World J Surg, 25, pp.660~668 (2001)
- Oishi K, "Association between cytokine removal by polymyxin B hemoperfusion and improved pulmonary oxygenation in patients with acute exacerbation of idiopathic pulmonary fibrosis", Cytokine, 61, pp.84~89 (2013)
- Enomoto N, "Treatment of acute exacerbation of idiopathic pulmonary fibrosis with direct hemoperfusion using a polymyxin B-immobilized fiber column improves survival", BMC Pulm Med, 15, pp.15~ (2015)
- Tanaka T, "IL-6 in inflammation, immunity, and disease", Cold Spring Harb Perspect Bi, 6, pp.a016295~ (2014)
- Papiris SA, "High levels of IL-6 and IL-8 characterize early-on idiopathic pulmonary fibrosis acute exacerbations", Cytokine, 102, pp.168~172 (2018)
- Kono M, "Evaluation of different perfusion durations in direct hemoperfusion with polymyxin B-immobilized fiber column therapy for acute exacerbation of interstitial pneumonias", Blood Purif, 32, pp.75~81 (2011)
- Abe S, "Neutrophil adsorption by polymyxin B-immobilized fiber column for acute exacerbation in patients with interstitial pneumonia : a pilot study", Blood Purif, 29, pp.321~326 (2010)
- Takada T, "Effects of direct hemoperfusion with polymyxin B-immobilized fiber on rapidly progressive interstitial lung diseases", Intern Med, 53, pp.1921~1926 (2014)
- Ichiyasu H, "Efficacy of direct hemoperfusion using polymyxin B-immobilized fiber column(PMX-DHP)in rapidly progressive interstitial pneumonias : results of a historical control study and a review of previous studies", Ther Adv Respir Dis, 11, pp.261~275 (2017)